Full Press Release Details
MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES
(AMOUNTS IN MILLIONS)
Table 3
2013
2012
% Change
% Change
1Q
2Q
Jun YTD
1Q
2Q
Jun YTD
3Q
4Q
Full Year
2Q
Jun YTD
TOTAL SALES (1)
$
10,671
$
11,010
$
21,681
$
11,731
$
12,311
$
24,041
$
11,488
$
11,738
$
47,267
-11
-10
PHARMACEUTICAL
8,891
9,310
18,201
10,082
10,560
20,642
9,875
10,085
40,601
-12
-12
Primary Care and Women’s Health
Cardiovascular
Zetia
629
650
1,279
614
632
1,246
645
676
2,567
3
3
Vytorin
394
417
810
444
445
889
423
435
1,747
-6
-9
Diabetes & Obesity
Januvia
884
1,072
1,956
919
1,058
1,977
975
1,134
4,086
1
-1
Janumet
409
474
883
392
411
802
405
452
1,659
16
10
Respiratory
Nasonex
385
325
711
375
293
668
292
308
1,268
11
6
Singulair
337
281
618
1,340
1,431
2,771
602
480
3,853
-80
-78
Dulera
68
79
147
39
50
89
52
67
207
57
66
Asmanex
40
49
89
48
51
99
42
44
185
-3
-9
Women’s Health & Endocrine
NuvaRing
151
171
322
146
157
303
156
164
623
9
6
Fosamax
137
144
281
184
186
370
152
154
676
-22
-24
Follistim AQ
122
134
257
116
125
241
111
116
468
8
6
Implanon
84
102
187
76
85
161
93
94
348
20
16
Cerazette
61
48
108
67
72
139
64
68
271
-34
-22
Other
Arcoxia
121
121
242
112
117
229
109
115
453
4
6
Avelox
36
29
65
73
44
117
30
55
201
-34
-45
Hospital and Specialty
Immunology
Remicade
549
527
1,076
519
518
1,037
490
549
2,076
2
4
Simponi
108
120
228
74
76
150
86
95
331
59
52
Infectious Disease
Isentress
362
412
775
337
398
735
399
381
1,515
4
5
Cancidas
162
163
326
145
166
311
163
145
619
-1
5
PegIntron
126
142
268
162
183
345
165
143
653
-22
-22
Invanz
110
120
230
101
110
211
118
116
445
9
9
Victrelis
110
116
226
111
126
238
149
115
502
-8
-5
Noxafil
65
71
136
59
66
125
66
68
258
7
9
Oncology
Temodar
216
219
434
237
225
461
227
229
917
-3
-6
Emend
116
135
250
102
145
247
111
131
489
-7
1
Other
Cosopt / Trusopt
105
103
209
124
105
229
102
113
444
-2
-9
Bridion
63
69
131
58
60
118
68
75
261
14
11
Integrilin
47
48
95
53
60
113
48
51
211
-20
-15
Diversified Brands
Cozaar / Hyzaar
267
255
522
336
337
674
295
315
1,284
-24
-23
Primaxin
84
85
168
88
104
192
109
83
384
-19
-12
Zocor
82
74
156
103
96
199
86
98
383
-23
-22
Propecia
68
67
135
108
100
208
104
112
424
-33
-35
Clarinex
61
64
125
134
140
273
64
56
393
-54
-54
Claritin Rx
76
40
115
87
48
134
47
63
244
-17
-14
Remeron
52
53
106
57
66
123
52
57
232
-19
-14
Proscar
39
58
98
51
55
106
55
56
217
7
-8
Maxalt
40
43
83
156
154
310
166
162
638
-72
-73
Vaccines
Gardasil
390
383
773
284
324
608
581
442
1,631
18
27
ProQuad, M-M-R II and Varivax
272
339
611
255
316
571
396
306
1,273
7
7
Zostavax
168
141
309
76
148
224
202
225
651
-5
38
RotaTeq
162
144
306
142
142
284
150
168
601
1
8
Pneumovax
111
108
219
112
101
213
160
208
580
7
3
Other Pharmaceutical (2)
1,022
1,115
2,136
1,066
1,034
2,102
1,065
1,161
4,333
8
2
ANIMAL HEALTH
840
851
1,691
821
865
1,686
815
898
3,399
-2
—
CONSUMER CARE (3)
571
490
1,061
554
552
1,106
451
395
1,952
-11
-4
Claritin OTC
177
78
256
169
145
314
118
100
532
-46
-19
Other Revenues (4)
369
359
727
274
333
608
347
360
1,315
8
20
Astra
262
245
507
186
223
409
255
251
915
10
24
* 100% or greater
Sum of quarterly amounts may not equal year-to-date amounts due to rounding.
(1) Only select products are shown.
(2) Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were $53 million and $86 million for the first and second quarters of 2013. Other Vaccines sales included in Other Pharmaceutical were $60 million, $75 million, $116 million, and $69 million for the first, second, third, and fourth quarters of 2012, respectively.
(3) The decrease in Consumer Care sales resulted from the ongoing termination in China of certain Consumer Care distribution arrangements and a reversal of sales previously made to those distributors, together with associated termination costs.
(4) Other revenues are primarily comprised of alliance revenue, miscellaneous corporate revenues and third party manufacturing sales.